trending Market Intelligence /marketintelligence/en/news-insights/trending/a6H9G5qw_NioZm2sa6q0iw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

UK drugs association drops legal battle over new cost constraints

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


UK drugs association drops legal battle over new cost constraints

The Association of the British Pharmaceutical Industry's board unanimously agreed to not appeal a high court's decision to turn down its application for a judicial review of the National Institute for Health and Care Excellence's new cost rules for drugs.

Previously, the trade association of biopharmaceutical companies in the U.K. sought to challenge NICE's policy that limits funding of drugs expected to cost the U.K.'s National Health Service more than £20 million per year in any of the first three years of use.

The application was rejected by High Court Honourable Justice Elisabeth Laing.